Phosphodiesterase type 4 inhibitor rolipram inhibits activation of monocytes during extracorporeal circulation.

@article{Sato2005PhosphodiesteraseT4,
  title={Phosphodiesterase type 4 inhibitor rolipram inhibits activation of monocytes during extracorporeal circulation.},
  author={Yukio Sato and Yuji Hiramatsu and Satoshi Homma and Makiko Sato and Shyoko Sato and Shunsuke Endo and Yasunori Sohara},
  journal={The Journal of thoracic and cardiovascular surgery},
  year={2005},
  volume={130 2},
  pages={346-50}
}
OBJECTIVE Cardiopulmonary bypass is associated with systemic inflammatory response syndrome and risk of multiorgan injury mediated by activated leukocytes. Phosphodiesterase type 4 is the predominant phosphodiesterase isozyme in leukocytes and plays a key role in the regulation of leukocyte activation. The aim of this study was to examine the effect of rolipram, a selective phosphodiesterase type 4 inhibitor, on functional changes of monocytes during simulated extracorporeal circulation… CONTINUE READING